344 related articles for article (PubMed ID: 24905058)
1. Liraglutide in the treatment of obesity.
Ng SY; Wilding JP
Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 agonists.
Padwal R
BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
[No Abstract] [Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
4. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
7. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
8. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide: a new treatment for type 2 diabetes.
Vilsboll T
Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
[TBL] [Abstract][Full Text] [Related]
10. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
11. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
13. Treatment evaluation of liraglutide in type 2 diabetes.
Kela R; Davies MJ
Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
[TBL] [Abstract][Full Text] [Related]
14. Incretin hormones and the satiation signal.
Holst JJ
Int J Obes (Lond); 2013 Sep; 37(9):1161-8. PubMed ID: 23295502
[TBL] [Abstract][Full Text] [Related]
15. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
[TBL] [Abstract][Full Text] [Related]
17. Recent advancements in drug treatment of obesity.
Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
Hall MJ; Adin CA; Borin-Crivellenti S; Rudinsky AJ; Rajala-Schultz P; Lakritz J; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():114-21. PubMed ID: 25625650
[TBL] [Abstract][Full Text] [Related]
20. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]